image credit- freepik
Japan-based Chugai Pharmaceutical and the University of California, San Francisco (UCSF) have entered into a Master Collaboration Agreement to advance drug discovery research.
The multi-year agreement establishes a framework to facilitate research collaborations in areas including the exploration of disease biology, the identification of novel drug targets, and the development of new therapeutic approaches. An initial research project is already underway with a UCSF principal investigator.
Under the agreement, Chugai and UCSF will leverage UCSF’s scientific innovation and translational research capabilities together with Chugai’s proprietary technologies, including antibody engineering, macrocyclic peptides (SnipeTide™), and small molecules, to advance early-stage research toward the next generation of innovative medicines.
The agreement marks a significant step in Chugai’s global open innovation strategy and its commitment to building deeper ties with leading US academic institutions.
